Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev Hematol 2010 Jun;3(3):255-60
Date
11/19/2010Pubmed ID
21082977Pubmed Central ID
PMC3793890DOI
10.1586/ehm.10.22Scopus ID
2-s2.0-77953494025 (requires institutional sign-in at Scopus site) 88 CitationsAuthor List
Brandow AM, Panepinto JAAuthor
Amanda Brandow DO Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentAnemia, Sickle Cell
Antisickling Agents
Blood Transfusion
Child
Drug Monitoring
Fear
Female
Hematopoietic Stem Cell Transplantation
Humans
Hydroxyurea
Male
Patient Compliance
Patient Freedom of Choice Laws
Risk Assessment
Treatment Outcome
Young Adult